分组1 - UnitedHealth Group reported quarterly earnings of $2.11 per share, exceeding the Zacks Consensus Estimate of $2.09 per share, but down from $6.81 per share a year ago, representing an earnings surprise of +0.83% [1] - The company posted revenues of $113.22 billion for the quarter ended December 2025, slightly missing the Zacks Consensus Estimate by 0.04%, and up from $100.81 billion year-over-year [2] - Over the last four quarters, UnitedHealth has surpassed consensus EPS estimates two times and topped revenue estimates only once [2] 分组2 - The stock has gained approximately 6.5% since the beginning of the year, outperforming the S&P 500's gain of 1.5% [3] - The current consensus EPS estimate for the upcoming quarter is $6.36 on revenues of $113.89 billion, and for the current fiscal year, it is $17.61 on revenues of $457.6 billion [7] - The Zacks Industry Rank for Medical - HMOs is in the bottom 7% of over 250 Zacks industries, indicating potential challenges for stock performance [8]

Core Viewpoint - UnitedHealth Group's stock has shown resilience with a recent increase, but upcoming earnings are expected to reflect a significant decline in earnings per share year-over-year [1][2]. Financial Performance - UnitedHealth Group closed at $347.75, up 2.75% from the previous trading session, outperforming the S&P 500's gain of 1.16% [1]. - The company is projected to report earnings of $2.09 per share on January 27, 2026, indicating a year-over-year decline of 69.31% [2]. - For the full year, earnings are estimated at $16.3 per share, reflecting a decrease of 41.07%, while revenue is expected to remain flat at $447.7 billion [3]. Analyst Estimates - Recent changes in analyst estimates are crucial for investors, as they often indicate the latest business trends and outlook [3]. - The consensus EPS projection has increased by 0.01% in the past 30 days, and UnitedHealth Group currently holds a Zacks Rank of 3 (Hold) [5]. Valuation Metrics - UnitedHealth Group has a Forward P/E ratio of 19.23, which is higher than the industry average of 15.58, suggesting it is trading at a premium [6]. - The company has a PEG ratio of 2.04, compared to the industry average of 1.04, indicating a higher valuation relative to projected earnings growth [7]. Industry Context - The Medical - HMOs industry, to which UnitedHealth Group belongs, has a Zacks Industry Rank of 215, placing it in the bottom 13% of over 250 industries [7][8].

Core Viewpoint - UnitedHealth Group is facing a significant year-over-year decline in earnings, while revenue is expected to grow, indicating mixed performance in the upcoming earnings report [2][3]. Group 1: Stock Performance - UnitedHealth Group (UNH) closed at $323.62, down 2.2% from the previous day, underperforming the S&P 500, which lost 0.35% [1]. - Over the past month, shares of UnitedHealth Group have appreciated by 2.07%, underperforming the Medical sector's gain of 5.67% but outperforming the S&P 500's gain of 1.2% [1]. Group 2: Earnings and Revenue Estimates - UnitedHealth Group is projected to report earnings of $2.07 per share, representing a year-over-year decline of 69.6% [2]. - The Zacks Consensus Estimate for revenue is projecting net sales of $113.53 billion, up 12.62% from the year-ago period [2]. - For the entire fiscal year, earnings are projected at $16.29 per share, a decline of 41.11%, while revenue is expected to be $447.97 billion, an increase of 11.91% from the prior year [3]. Group 3: Analyst Estimates and Rankings - Recent adjustments to analyst estimates for UnitedHealth Group indicate changing business trends, with positive changes suggesting a favorable outlook on business health and profitability [4]. - The Zacks Rank system, which includes estimate changes, currently ranks UnitedHealth Group at 3 (Hold) [6]. Group 4: Valuation Metrics - UnitedHealth Group has a Forward P/E ratio of 20.32, which is a premium compared to the industry average Forward P/E of 13.6 [7]. - The company has a PEG ratio of 2.16, compared to the Medical - HMOs industry average PEG ratio of 1.28 [8]. Group 5: Industry Context - The Medical - HMOs industry holds a Zacks Industry Rank of 202, placing it in the bottom 19% of all 250+ industries [8]. - Research indicates that the top 50% rated industries outperform the bottom half by a factor of 2 to 1 [9].

Group 1: Stock Performance - UnitedHealth Group (UNH) closed at $319.97, reflecting a +2.71% change from the previous day, outperforming the S&P 500's gain of 0.98% [1] - Over the last month, UNH shares decreased by 13.57%, underperforming the Medical sector's gain of 4.76% and the S&P 500's loss of 2.79% [1] Group 2: Earnings Projections - Upcoming EPS for UnitedHealth Group is projected at $2.07, indicating a significant 69.60% decline compared to the same quarter last year [2] - Revenue is expected to reach $113.53 billion, representing a 12.62% increase from the year-ago quarter [2] Group 3: Fiscal Year Estimates - For the entire fiscal year, earnings are estimated at $16.29 per share, reflecting a -41.11% change from the previous year, while revenue is projected at $447.97 billion, indicating an +11.91% change [3] - Recent adjustments to analyst estimates suggest a favorable outlook on the business health and profitability [3] Group 4: Valuation Metrics - UnitedHealth Group has a Forward P/E ratio of 19.13, which is higher than the industry average of 11.81, indicating a premium valuation [6] - The company has a PEG ratio of 2.03, compared to the Medical - HMOs industry's average PEG ratio of 1.16 [7] Group 5: Industry Ranking - The Medical - HMOs industry currently holds a Zacks Industry Rank of 203, placing it within the bottom 18% of over 250 industries [7] - The Zacks Rank system, which assesses the strength of industry groups, shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1 [8]

Core Insights - The Joint Corp. reported quarterly earnings of $0.02 per share, exceeding the Zacks Consensus Estimate of a loss of $0.01 per share, representing an earnings surprise of +300.00% [1] - The company posted revenues of $13.38 million for the quarter ended September 2025, surpassing the Zacks Consensus Estimate by 0.84%, but down from $30.2 million year-over-year [2] - The stock has underperformed the market, losing about 22% since the beginning of the year compared to the S&P 500's gain of 15.6% [3] Earnings Performance - Over the last four quarters, The Joint has surpassed consensus EPS estimates two times and topped consensus revenue estimates three times [2] - The current consensus EPS estimate for the coming quarter is $0.16 on revenues of $15.04 million, and for the current fiscal year, it is $0.03 on revenues of $54.63 million [7] Market Outlook - The company's earnings outlook will be crucial for future stock performance, with management's commentary on the earnings call expected to influence investor sentiment [3][4] - The Zacks Rank for The Joint is currently 3 (Hold), indicating that shares are expected to perform in line with the market in the near future [6] Industry Context - The Medical - HMOs industry, to which The Joint belongs, is currently in the bottom 27% of over 250 Zacks industries, suggesting potential challenges ahead [8]

Core Insights - Humana reported quarterly earnings of $3.24 per share, exceeding the Zacks Consensus Estimate of $2.91 per share, but down from $4.16 per share a year ago, indicating an earnings surprise of +11.34% [1] - The company achieved revenues of $32.65 billion for the quarter ended September 2025, surpassing the Zacks Consensus Estimate by 2.09% and up from $29.3 billion year-over-year [2] - Humana has outperformed consensus EPS estimates three times in the last four quarters and has also topped revenue estimates three times during the same period [2] Earnings Outlook - The future performance of Humana's stock will largely depend on management's commentary during the earnings call and the sustainability of the stock's immediate price movement based on the recently released numbers [3][4] - The current consensus EPS estimate for the upcoming quarter is -$3.70 on revenues of $31.77 billion, while for the current fiscal year, it is $17.05 on revenues of $128.21 billion [7] Industry Context - The Medical - HMOs industry, to which Humana belongs, is currently ranked in the bottom 26% of over 250 Zacks industries, suggesting that the overall industry outlook may negatively impact Humana's stock performance [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can be tracked by investors or through tools like the Zacks Rank [5][6]

Core Insights - Select Medical (SEM) reported quarterly earnings of $0.23 per share, exceeding the Zacks Consensus Estimate of $0.18 per share, but down from $0.5 per share a year ago, representing an earnings surprise of +27.78% [1] - The company posted revenues of $1.36 billion for the quarter ended September 2025, surpassing the Zacks Consensus Estimate by 2.87%, but down from $1.76 billion year-over-year [2] - Select Medical shares have declined approximately 24.2% year-to-date, contrasting with the S&P 500's gain of 17.2% [3] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is $0.26 on revenues of $1.36 billion, and for the current fiscal year, it is $1.18 on revenues of $5.38 billion [7] - The estimate revisions trend for Select Medical was mixed prior to the earnings release, resulting in a Zacks Rank 3 (Hold) for the stock, indicating expected performance in line with the market [6] Industry Context - The Medical - HMOs industry, to which Select Medical belongs, is currently ranked in the bottom 35% of over 250 Zacks industries, suggesting potential challenges ahead [8] - Humana (HUM), another company in the same industry, is expected to report quarterly earnings of $2.91 per share, reflecting a year-over-year decline of -30.1%, with revenues anticipated to be $31.98 billion, up 9.1% from the previous year [9][10]

Group 1: Earnings Performance - Cigna reported quarterly earnings of $7.83 per share, exceeding the Zacks Consensus Estimate of $7.7 per share, and up from $7.51 per share a year ago, representing an earnings surprise of +1.69% [1] - The company posted revenues of $69.57 billion for the quarter ended September 2025, surpassing the Zacks Consensus Estimate by 3.59%, compared to $63.7 billion in the same quarter last year [2] Group 2: Stock Performance and Outlook - Cigna shares have increased by approximately 8.3% since the beginning of the year, while the S&P 500 has gained 17.2% [3] - The current consensus EPS estimate for the upcoming quarter is $8.04 on revenues of $67.81 billion, and for the current fiscal year, it is $29.69 on revenues of $267.39 billion [7] Group 3: Industry Context - The Medical - HMOs industry, to which Cigna belongs, is currently ranked in the bottom 35% of over 250 Zacks industries, indicating potential challenges for stock performance [8] - The Joint Corp., another company in the same industry, is expected to report a quarterly loss of $0.01 per share, reflecting a year-over-year change of -125%, with revenues anticipated to be $13.27 million, down 56.1% from the previous year [9]

Core Insights - UnitedHealth Group's stock has not experienced the anticipated post-earnings rally, but there are signs of operational stabilization [1] - The company reported mixed Q3 results, with adjusted earnings exceeding expectations but sales slightly missing estimates [3][4] - UnitedHealth raised its full-year adjusted EPS guidance, indicating a more optimistic outlook [6] Financial Performance - Q3 adjusted earnings were $2.92 per share, surpassing expectations of $2.75, but down from $7.15 in the same quarter last year [3] - Q3 sales reached $113.16 billion, a 12% increase from $100.82 billion a year ago, but slightly below estimates of $113.35 billion [4] - The company has raised its full-year adjusted EPS guidance to at least $16.25, above the previous floor of $16.00 and the Zacks Consensus of $16.15 [6] Leadership and Future Outlook - CEO Stephen Hemsley highlighted solid earnings growth prospects for 2026 and beyond, despite warnings of potential membership losses in Medicare Advantage and ACA plans [8] - Annual EPS is projected to rebound to $17.39 in fiscal 2026 according to Zacks' estimates [8] Valuation and Dividend - UnitedHealth's stock trades at a forward earnings multiple of 22.7X, slightly below the S&P 500 benchmark and the industry average of 18X [10] - The company offers a 2.4% annual dividend yield, which is higher than the benchmark's 1.07% and the industry average of 2.11% [11] - UnitedHealth has a history of raising dividends for at least 25 consecutive years, with a 12.91% annualized dividend growth rate over the last five years [12][14]

Core Viewpoint - Centene (CNC) reported quarterly earnings of $0.5 per share, significantly exceeding the Zacks Consensus Estimate of a loss of $0.21 per share, marking an earnings surprise of +338.10% [1] - The company generated revenues of $49.69 billion for the quarter ended September 2025, surpassing the Zacks Consensus Estimate by 4.35% and showing an increase from $42.02 billion year-over-year [2] Financial Performance - Centene's earnings for the previous year were $1.62 per share, indicating a decline in profitability [1] - The company has surpassed consensus EPS estimates three times over the last four quarters [2] - The current consensus EPS estimate for the upcoming quarter is -$0.87, with projected revenues of $47.41 billion, while the estimate for the current fiscal year is $1.69 on $190.45 billion in revenues [7] Market Position - Centene shares have underperformed, losing about 45.2% since the beginning of the year, compared to a 17.2% gain in the S&P 500 [3] - The Zacks Rank for Centene is currently 5 (Strong Sell), indicating expectations of underperformance in the near future [6] Industry Outlook - The Medical - HMOs industry, to which Centene belongs, is currently ranked in the bottom 26% of over 250 Zacks industries, suggesting a challenging environment [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which could impact Centene's stock performance [5]